Frontline (FRO) Stock

Frontline plc offers a high dividend yield of 12%, but has a history of unpredictable dividend cuts, making it suitable for aggressive investors. Despite geopolitical risks, oil prices are expected to stay above $70/barrel, benefiting midstream companies like FRO, which are crucial for oil transport. Earnings estimates for FRO are positive, with expected 25% YoY revenue growth, but the company has a history of disappointing earnings reports.

Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024

Wayne, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Frontline Education, a leading provider of administration software purpose-built for educators in K-12, today announced a new partnership with Equifax®, a global data, analytics, and technology company, to offer The Work Number®, a robust income and employment verification service, to its Enterprise Resource Planning (ERP) clients in Texas and California.

--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly

I maintain a Buy rating for Frontline due to its large, modern fleet, strong balance sheet, and attractive dividend yield. FRO's fleet consists of 82 tankers with an average age of 6.2 years. 56% of the ships are equipped with scrubbers. Despite high leverage, FRO's operating figures and cash reserves adequately cover debt service costs, ensuring financial stability.

MILWAUKEE, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Verizon Frontline Crisis Response Team recently completed a deployment in support of the Milwaukee Police Department, one of the lead agencies responsible for coordination of all public safety activity during the Republican National Convention.

Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine Company anticipates new data set to bolster existing compelling data reported to date, including efficacy outcomes more than double the benchmarks* Outcomes also expected to identify recommended Phase 2 dose APVO436 renamed as mipletamig: Aptevo adopts new generic name for future use SEATTLE, WA / ACCESSWIRE / August 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today, announced initiation of the Company's Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate APVO436 in combination with venetoclax + azacitidine for frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts.

Frontline plc stock is rated as a buy-to-strong buy opportunity after a recent drop in share price. Growth opportunities in the marine shipping industry outweigh risks, with demand for crude tankers expected to remain high in the coming years. Frontline plc has a high dividend yield of 10.9% and strong financial metrics, despite accumulating debt to finance its fleet of tankers.

TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy for Newly Diagnosed AML has been Submitted to the 2025 Annual Meeting of the American Society of Hematology (ASH) SAN DIEGO and TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months ended June 30, 2024, and provided a corporate update. “We are pleased that our triplet protocol of tuspetinib with venetoclax and azacitidine (TUS+VEN+AZA) has been allowed to proceed at the 40 mg dose of tuspetinib, a dose that as a single agent and in doublet therapy has been shown to be safe and active,” said William G.